[1] BAUER P R, SAMPATHKUMAR P. Methicillin-resistant Staphylococcus aureus infection in ICU:What is the best prevention strategy?[J]. Crit Care Med, 2017, 45(8):1413-1414.
[2] ZAJONZ D, WUTHE L, RODLOFF A C, usw. Infektionen von Hüft-und Knieendoprothesen[J]. Der Chirurg, 2016, 87(4):332-339.
ZAJONZ D, WUTHE L, RODLOFF A C, et al. Infections of the hip and knieendoprothesen[J]. The Surgeon, 2016, 87(4):332-339.(in German)
[3] OKADA T, SATO Y, TOYONAGA Y, et al. Nationwide survey of Streptococcus pneumoniae drug resistance in the pediatric field in Japan[J]. Pediatr Int, 2016, 58(3):192-201.
[4] MILLER W R, MURRAY B E, RICE L B, et al. Vancomycin-resistant enterococci:therapeutic challenges in the 21st century[J]. Infect Dis Clin North Am, 2016, 30(2):415-439.
[5] POKROVSKAYA V, BAASOV T. Dual-acting hybrid antibiotics:a promising strategy to combat bacterial resistance[J]. Expert Opin Drug Discov, 2010, 5(9):883-902.
[6] DALY J S, ELIOPOULOS G M, REISZNER E, et al. Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds[J]. J Antimicrob Chemother, 1988, 21(6):721-730.
[7] YAGI B H, ZURENKO G E. In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria[J]. Anaerobe, 1997, 3(5):301-306.
[8] SENIOR K. FDA approves first drug in new class of antibiotics[J]. Lancet, 2000, 355(9214):1523.
[9] IM W B, CHOI S H, PARK J Y, et al. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent[J]. Eur J Med Chem, 2011, 46(4):1027-1039.
[10] KLUPP E M, BOTH A, BELMAR CAMPOS C, et al. Tedizolid susceptibility in linezolid-and vancomycin-resistant Enterococcus faecium isolates[J]. Eur J Clin Microbiol Infect Dis, 2016, 35(12):1957-1961.
[11] HOWE R A, WOOTTON M, NOEL A R, et al. Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid[J]. Antimicrob Agents Chemother, 2003, 47(11):3651-3652.
[12] EDNIE L M, RATTAN A, JACOBS M R, et al. Antianaerobe activity of RBX 7644(ranbezolid), a new oxazolidinone, compared with those of eight other agents[J]. Antimicrob Agents Chemother, 2003, 47(3):1143-1147.
[13] GORDEEV M F, LUEHR G W, PATEL D V, et al. Preparation of N-acyl-3-aryl-2-oxooxazolidine-5-methanammines as bactericides:WO, 2001009107[P]. 2000-07-26.
[14] JADHAVAR P S, VAJA M D, DHAMELIYA T M, et al. Oxazolidinones as anti-tubercular agents:discovery, development and future perspectives[J]. Curr Med Chem, 2015, 22(38):4379-4397.
[15] BARBACHYN M R, FORD C W. Oxazolidinone structure-activity relationships leading to linezolid[J]. Angew Chem Int Ed Engl, 2003, 42(18):2010-2023.
[16] DAS B, RUDRA S, YADAV A, et al. Synthesis and SAR of novel oxazolidinones:discovery of ranbezolid[J]. Bioorg Med Chem Lett, 2005, 15(19):4261-4267.
[17] XIN Q S, FAN H X, GUO B, et al. Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents[J]. J Med Chem, 2011, 54(21):7493-7502.
[18] LESHER G Y, FROELICH E J, GRUETT M D, et al. 1,8-naphthyridine derivatives. A new class of chemotherapeutic agents[J]. J Med Pharm Chem, 1962, 91:1063-1065.
[19] CORREIA S, POETA P, HÉBRAUD M, et al. Mechanisms of quinolone action and resistance:where do we stand?[J]. J Med Microbiol, 2017, 66(5):551-559.
[20] CROSS R M, MONASTYRSKYI A, MUTKA T S, et al. Endochin optimization:structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity[J]. J Med Chem, 2010, 53(19):7076-7094.
[21] MAIGNAN J R, LICHOROWIC C L, GIARRUSSO J, et al. ICI 56,780 Optimization:Structure-activity relationship studies of 7-(2-phenoxyethoxy)-4(1H)-quinolones with antimalarial activity[J]. J Med Chem, 2016, 59(14):6943-6960.
[22] OUAHROUCH A, IGHACHANE H, TAOURIRTE M, et al. Benzimidazole-1,2,3-triazole hybrid molecules:synthesis and evaluation for antibacterial/antifungal activity[J]. Arch Pharm (Weinheim), 2014, 347(10):748-755.
[23] KAROLI T, MAMIDYALA S K, ZUEGG J, et al. Structure aided design of chimeric antibiotics[J]. Bioorg Med Chem Lett, 2012, 22(7):2428-2433.
[24] ROBERTSON G T, BONVENTRE E J, DOYLE T B, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic:microbiology profiling studies with staphylococci and streptococci[J]. Antimicrob Agents Chemother, 2008, 52(7):2324-2334.
[25] POKROVSKAYA V, BELAKHOV V, HAINRICHSON M, et al. Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics[J]. J Med Chem, 2009, 52(8):2243-2254.
[26] HUBSCHWERLEN C, SPECKLIN J L, SIGWALT C, et al. Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids[J]. Bioorg Med Chem, 2003, 11(10):2313-2319.
[27] GORDEEV M F, HACKBARTH C, BARBACHYN M R, et al. Novel oxazolidinone-quinolone hybrid antimicrobials[J]. Bioorg Med Chem Lett, 2003, 13(23):4213-4216.
[28] HUBSCHWERLEN C, SPECKLIN J L, BAESCHLIN D K, et al. Structure-activity relationship in the oxazolidinone-quinolone hybrid series:influence of the central spacer on the antibacterial activity and the mode of action[J]. Bioorg Med Chem Lett, 2003, 13(23):4229-4233.
[29] T·卡布思纳, A·达尔霍夫. 含噁唑烷酮-喹诺酮的联合疗法在治疗细菌感染中的应用:中国, CN105246476A[P]. 2016-01-13.
KAPSNER T, DALHOFF A. Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections:China, CN105246476A[P]. 2016-01-13. (in Chinese)
[30] 克里斯蒂安·哈伯舒兰, 菲利普·潘彻德, 克里斯汀·西格瓦尔特,等.作为抗菌化合物的恶唑烷酮-喹诺酮混合物:中国,CN101238135B[P]. 2011-05-11.
PANCHAUD P, SIGWALT C, HUBSCHWERLEN C, et al. Oxazolidinone-quinolone hybrids as antibacterial compounds:China, CN101238135B[P]. 2011-05-11. (in Chinese)
[31] ENDRES B T, BASSèRES E, ALAM M J, et al. Cadazolid for the treatment of Clostridium difficile[J]. Expert Opin Investig Drugs, 2017, 26(4):509-514.
[32] LOCHER H H, CASPERS P, BRUYÈRE T, et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections[J]. Antimicrob Agents Chemother, 2014, 58(2):901-908.
[33] CHILTON C H, CROWTHER G S, BAINES S D, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection[J]. J Antimicrob Chemother, 2014, 69(3):697-705.
[34] RASHID M U, LOZANO H M, WEINTRAUB A, et al. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden[J]. Anaerobe, 2013, 20:32-35.
[35] RASHID M U, DALHOFF A, WEINTRAUB A, et al. In vitro activity of MCB3681 against Clostridium difficile strains[J]. Anaerobe, 2014, 28:216-219.
[36] LOCHER H H, SEILER P, CHEN X H, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections[J]. Antimicrob Agents Chemother, 2014, 58(2):892-900.
[37] LOUIE T, NORD C E, TALBOT G H, et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection[J]. Antimicrob Agents Chemother, 2015, 59(10):6266-6273.
[38] BALDONI D, GUTIERREZ M, TIMMER W, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile:safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses[J]. J Antimicrob Chemother, 2014, 69(3):706-714.
[39] GEHIN M, DESNICA B, DINGEMANSE J. Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection[J]. Int J Antimicrob Agents, 2015, 46(5):576-581. |